Bio-Rad Laboratories (NYSE:BIO.B) Stock Price Up 15.3% - Here's What Happened

Key Points

• Bio-Rad Laboratories (NYSE:BIO.B) stock surged 15.3% to $284.88, marking a significant increase from its previous close of $247.05, with trading volume up 493%.
• The company reported $2.61 EPS for the last quarter, with a net margin of 12.50% and revenue of $651.60 million.
• Bio-Rad operates in the life science research and clinical diagnostics sectors, providing various laboratory instruments and reagents globally.

Bio-Rad Laboratories, Inc. (NYSE:BIO.B - Get Free Report) rose 15.3% during mid-day trading on Friday . The company traded as high as $284.88 and last traded at $284.88. Approximately 300 shares changed hands during mid-day trading, an increase of 493% from the average daily volume of 51 shares. The stock had previously closed at $247.05.

Bio-Rad Laboratories Stock Performance

The firm has a market capitalization of $7.75 billion, a price-to-earnings ratio of 24.29 and a beta of 0.81. The stock's fifty day moving average is $260.69 and its two-hundred day moving average is $250.63. The company has a quick ratio of 3.67, a current ratio of 5.12 and a debt-to-equity ratio of 0.17.

Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $2.61 EPS for the quarter. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The firm had revenue of $651.60 million for the quarter.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.